Figure 2.

High heterogeneity among patients with metastasized CRPC after multiple different therapies at the stage when they are referred for Lu-177-PSMA therapies. The diagram gives a short overview of the different potentially activated signaling pathways on progression of prostate cancer cells that might become androgen-receptor- and prostate-specific antigen-negative over time, which can lead to apoptosis resistance and tumor recurrence or progression. ADT = androgen deprivation therapy, AR = androgen receptor, miRNA = microRNA, PSA = prostate-specific antigen.